,src,lang,text
0,"











Dubla capcană pentru bugetul 2020 de la Ministerul Sănătăţii
06 Nov 2019, 10:20 by Dragos Damian
Opinie
Cu 75 Euro de persoana alocati pentru medicamente, ultimul loc in UE, Romania are un ecart urias de recuperat in urmatorul ciclu electoral. Nu este foarte clar de unde se pot luat bani pentru a fi decontate promisiunile de acces la medicamente de ultima generatie, dar este sigur ca Domnii Florin Citu si Victor Costache vor descoperi o situatie paradoxala in bugetul de venituri si cheltuieli de la Sanatate.
Astfel, un calcul estimativ arata ca pentru 2020 exista un deficit de circa 1,2-1,5 mld lei privind finantarea medicamentelor datorita introducerii de circa 70 medicamente noi in uz in perioada 2017-2019, fara sa fi existat o sursa de finantare. Doar cele 17 medicamente introduse in uz la inceputul lui octombrie au un cost estimat anual de peste 300 mil lei;
Desi s-a mentionat in referatele de aprobare ca aceste medicamente au “impact bugetar neutru” CNAS le-a decontat, dar a transferat finantarea lor catre producatori prin taxa clawback; astfel incat taxa a ajuns la 25% in ultimele 5-6 trimestre si se asteapta a fi 30% in T3 si 35% in T4. Si asta in contextul in care bugetul de medicamente pentru 2019 a fost majorat cu o suma de 80 mil lei, evident insuficienta.
Surpriza in bugetele din ultimii 3 ani si capcana pentru bugetul din 2020 este ca sumele incasate  din taxa clawback – 1.2-1.5 mld lei - se constituie in venituri bugetare si sunt incasate in trezorerie si utilizate acolo unde este nevoie de ele, deci nu se intorc in sanatate.
Astfel incat, avem de fapt o dubla capcana in bugetul 2020, care poate conduce la un deficit suplimentar de 2 mld lei, circa 1-1,5% din PIB:

este necesara o suplimentare bugetara de minim 1 mld lei pentru ca taxa clawback sa devina sustenabila si producatorii sa nu continue sa retraga medicamente din uz;
suplimentarea de cheltuieli va duce la o reducere proportionala de venituri din taxa clawback cu 1 mld lei.

Asadar, daca in constructia bugetului din 2020 nu vor fi gasite 2 mld lei pentru finantarea medicamentelor, crizele vor continua, producatorii vor retrage medicamente, etc. Dar este absolut sigur ca proiectul de buget lasat mostenire nu prevede o corectie de acest fel.
Inca doua puncte importante care trebuie mentionate, pentru ca Dnii Citu si Costache sa aiba imaginea completa:

Guvernul trebuie sa gaseasca resurse de circa 12 mld lei in urmatorii 3 ani pentru finantarea contractelor cost volum si cost volum rezultat – pana acum erau utilizate credite de anagajament, care paseaza deficitul de la un an la altul;


producatorii de medicamente din tara trebuie sa plateasca taxa clawback desi nu au venituri suplimentare, neavand medicamente noi decontate de CNAS. Primul Ministru Ludovic Orban a spus intre altele la investire “….in domeniul sanatatii trebuie sa sistam practica prin care omoram medicamente produse in tara pentru altele mult mai scumpe…”. Il asigur pe Dl Orban ca la 4% cota de piata nu mai avem industrie locala de medicamente din cauza taxei clawback - orice ar spune stirile care apar in fiecare zi, dispar medicamentele ieftine, produse in tara, nu cele scumpe, care pot rezista la socuri fiscale suplimentare.

Daca Sanatatea are un deficit de finantare de circa 2 miliarde lei, ma intreb ce deficite exista la alte ministere. Vom afla in curand.


",ro,"











Double trap for the 2020 budget from the Ministry of Health
06 Nov 2019, 10:20 by Dragos Damian
Opinion
With 75 Euro per person allocated for medicines, the last place in the EU, Romania has a huge gap to recover in the next election cycle. It is not very clear where the money can be taken to settle the promises of access to last generation medicines, but it is certain that Messrs Florin Citu and Victor Costache will discover a paradoxical situation in the budget of health revenues and expenses.
Thus, an estimation calculation shows that for 2020 there is a deficit of about 1.2-1.5 billion lei regarding the financing of medicines due to the introduction of about 70 new drugs in use during the period 2017-2019, without having been a source of financing. Only the 17 drugs introduced for use at the beginning of October have an estimated annual cost of over 300 million lei;
Although it was mentioned in the approval reports that these drugs had ""neutral budgetary impact"", CNAS settled them, but transferred their financing to the producers through the clawback tax; so the tax has reached 25% in the last 5-6 quarters and is expected to be 30% in Q3 and 35% in Q4. And this in the context in which the drug budget for 2019 was increased by an amount of 80 million lei, obviously insufficient.
The surprise in the budgets of the last 3 years and the trap for the 2020 budget is that the amounts collected from the clawback tax - 1.2-1.5 billion lei - are constituted in budget revenues and are collected in the treasury and used where they are needed, so they do not return in health.
So, in fact, we have a double trap in the 2020 budget, which can lead to an additional deficit of 2 billion lei, about 1-1.5% of GDP:

a supplementary budget of at least 1 billion lei is required in order for the clawback tax to become sustainable and the producers not to continue withdrawing medicines from use;
additional expenses will lead to a proportional reduction of revenues from the clawback tax by 1 billion lei.

Therefore, if in the construction of the 2020 budget no MDL 2 billion will be found for drug financing, the crises will continue, the producers will withdraw medicines, etc. But it is absolutely certain that the draft budget left behind does not provide for such a correction.
Two other important points that need to be mentioned, in order for Mrs Citu and Costache to have the complete image:

The government has to find resources of about 12 billion lei in the next 3 years to finance the contracts cost volume and cost volume result - until now they were used commitment loans, which passes the deficit from one year to another;


drug manufacturers in the country have to pay the clawback tax even though they have no additional income, not having new drugs settled by CNAS. Prime Minister Ludovic Orban said among other things about the investment ""... in the field of health we must stop the practice of killing drugs produced in the country for more expensive others ..."". I assure Mr. Orban that at 4% of the market share we no longer have the local drug industry because of the clawback tax - whatever the news that appears every day, cheap drugs, produced in the country, not expensive ones, that can withstand additional tax shocks.

If the Health has a financing deficit of about 2 billion lei, I wonder what deficits exist in other ministries. We'll find out soon.


"
